¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º <P~pn!F}  
w"{mDL}c  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ |"g+p)A  
H S)$|m_  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) s}qtM.^W  
,n{R,]y\  
1. ICAM-1 yXQ 28A  
+;T\:'CU  
2. interleukin 12(IL-12) #(}'G*  
&'k :?@J[  
3. tumor infiltrating lymphocyte 068DC_  
oT0:Ny  
4. TCR/CD3 complex c HC1l  
;b}cn!U]  
5. hematopoietin receptor family @ 3rJ$6W  
h t3P@;  
6. individual idiotype(IdI) OP|X-  
!5 ?<QKOe  
7. integrin RR2M+vQ  
(&-I-#i  
8. colony-stimulatory factor (CSF) {A~3/M%74;  
P~84#5R1  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© %?3$~d\n  
[HhaBy9  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? :Wihb#TO)  
M?5voV*  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ Yyw9IYB;  
.pG`/[*a  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠsf O{.#5<  
x \I uM  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ *x_e] /}  
n\< uT1n  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) c_t7<  
<kJ`qbOU  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ ,Iru_=Wk~  
3lbGG42:  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) 7X8*7'.2  
nt@uVwfQ  
3. immunoglobulin superfamily (IgSF) "MD 6<H  
e:K'e2  
4. selectin (,tL(:c  
{P 3gMv;  
5. anti-idiotypic antibody (¦ÁId) ol~ tfS  
RRro.r,  
6. major histocompatibility complex(MHC) |"[;0)dw^  
$KBW{  
7. immunotolerance aWNj l  
t~ $8sG\  
8. biological reponse modifier(BRM) B`w8d[cL7  
G *<g%"  
9. immune reponse gene (Ir gene) D&=+PAX  
><$V:nsEO  
10. reshaped antibody (or reconstituted antibody) =@&>r5W 1  
p}JGx^X ~  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© '+GY6Ecg  
3#aLCpVla  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ =BbXSwv'(  
PP/#Z~.M  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? GnC s_[*&r  
1(Z+n,Hh  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ W e*uZ?+  
Q(R -8"  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? ?0-3J )kW  
l\!`ZhM,  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 9!0-~,o  
tOZ-]>U  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? YgtW(j[  
3Vk\iJ  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ma/<#l^}  
sQ&<cBs2  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 4^9qs%&  
"Y"`'U=v  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? Hq&MePl[  
*|cs_,3  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ oW>e.}d!  
xa 967Ki9"  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: P,7R/-u5D  
uLfk>&hc  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: V0*MY{x #S  
@PK 1  
ÃâÒßѧ 0LTsWCUQ6e  
"|N0oEG&  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© i3) 7Qa[  
dZddo z_  
1. CD8 LaL{ ^wP  
8M]QDgd.  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) ty@D3l  
R <&U]%FD  
3. immunoglobulin fold(Ig fold) )Ofwfypc  
YllW2g:  
4. cadherin (Ca-dependent cell adhesion moleculers) q AsTiT6r  
f'tQLF[r<  
5. idiotype-anti-idiotypic antibody immune network theory d_ &~^*>  
$dKo}  
6. HLA class II antigen #8%~u+"N  
R-2Aby ts2  
7. complementarity-determining region (CDR) BDX>J3h  
/<J5?H  
8. perforin(or pore-forming protein ,PFP) Bi0&F1 ZC!  
b8 6c[2  
9. high affinity IL-2 receptor }!WuJz"  
N0YJ'.=8,  
10. artificial active immunization ?9~|K/`l  
bV*q~ @xh  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© /g!X[rn7Q  
uK[gI6M  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠg{hbq[>X]  
#*  8^ar<  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 Gd|jE  
R1/mzPG  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ uzT>|uu$  
bGi k~  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ h 3p~\%^  
rWp+kV[Ec>  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ |+1k7S  ,  
CSr2\ogT  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? )!sjXiC!h  
T 6=~vOzTJ  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ "@itn  
? Lr: >  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 2K2*UC`f  
K` <`l  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ :]`JcJ  
eGI&4JgJ.  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ (U*Zz+ R   
/ KKA/  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© uJJP<mDgA  
U5j0i]  
1. immunoglobulin gene rearrangement XK yW  
)GJlQ1x  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) 0Pg@%>yb~  
!jN$U%/,%.  
3. flow cytometry(FCM) ^ANz=`N5,  
/O$)m[  
4. carrier effect fXAD~7T*s  
* Vymb  
5. positive selection of T lymphocytes in thymus BWsD~Ft  
[Mlmn$it  
6. mouse TH1(Th1) and TH2(Th2) subsets T`)uR* $  
fq0[7Yb  
7. perforin (pore-forming protein ,PFP) =L}$#Y8?  
7 6S>xnN  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) |r53>,oR<:  
S3YAc4  
9. SH-2(src-homology region 2) |1Ko5z  
BsN~Z!kd  
10. Ab2¦Â (internal image) )"y]_}  
Py#iC#g~  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© "C [uz&  
m{0u+obi&w  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? , -S n  
~8G cWy6  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? |n.ydyu`  
h3kBNBI )  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠWFFpW{  
WWWfQ_u2  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ 0qD.OF)8  
!<MW*7P=  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠDR#[\RzNI  
DX#F]8bWl  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) j~rarR@NB)  
9:6 d,^X  
ÃâÒßѧרҵ£º 7S9Q{  
wenJ(0L|  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ Y{ 2xokJ N  
j<* `?V^  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? <x2 F5$@  
)Z2t=&Nw  
´«È¾²¡Ñ§×¨Òµ£º t ~"DQq E  
)?PRG=  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ ._z[T@!9  
6 _\j_$  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ?YbZVoD)J  
A?8 29<  
Ïû»¯×¨Òµ£º CDM==Xa*  
mF !=H%  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ 3 ,?==?  
gJ>HFid_C  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? L)ry!BuHI  
o<-+y\J8K  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ ?V&[U  
sIJ37;ZA  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 8W_X&X?Q  
bz? *#S  
1. Fas(CD95)/FasL h&6x.ps@  
8Cr?0Z  
2. common chain of cytokine receptor jP";ll|c  
qlg~W/  
3 . TCR/CD3 complex P!";$]+  
f(E  'i>  
4. negaive selection of thymocytes s"|N-A=cS  
ngJES` 0d  
5. artificial active immune "zO+!h'o  
J)n g,i  
6. anti-idiotypic !2N#H~{  
1q! 6Sny@  
7. IgSF f:TC;K  
BI=Ie?  
8. Integrin 8C=Y(vPk2  
%;PPu$8K9  
9. chemokine T+2I:W%  
1W HR;!u  
10. B7/CD28 $/45*  
9ffRY,1@  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© zq]V6.]J  
3<msiC P  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ @Cm"lv.hz  
a(8]y.`Tv  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 'eqvK|Uj:  
AJ:@c7:eS  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ $X~=M_ W  
lLtC9:  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ Ze Shn  
g)&-S3\  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ /IV:JVT  
{ Rw~G&vQ  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ D?5W1m]E,s  
GJy,)EO6{  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Z@C D1+G  
R?|_` @@A  
1. B7/CD28 YN>#zr+ ~  
Cv$TNkP*  
2. Th1 subset Z^ G riL  
'T|.<u@~  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© n{' [[2U  
qs-:JmA_w  
4. antibody affinity maturation X?7$JV-:  
R?&S]?H  
5. AP-1 6gR= e+  
Y?%6af+  
6. single chain variable fragment£¨ScFv£© KP<J~+_ik  
A<.Q&4jb  
7. NK cell receptor M;43F*   
Yaa M-o  
8. Zinkernagel-Doherty phenomenon 8v]{ 5  
VJR'B={h  
9. Ig fold WVN Q}KY  
[#9ij3vxd  
10. CD40/CD40L Rthu8NKn  
'Ux_X:,:;  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© R<U?)8g,h~  
xwRnrWd^6  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 'Vrev8D  
=AKW(v  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ BO9Z "|"  
5r+0^UAO:J  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Uv+pdRXn  
l.34 h  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ U|Jo[4A  
n]$vCP  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ no/]Me!j=  
tm|lqa  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ XsG]-Cw  
eY(usK  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ 18n84RkI9  
}agl:~C  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© asq/_`  
52["+1g\  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 5{u6qc4FW  
c0qv11,:t  
1.Co-stimulators (or co-stimulating molecules) 8;!Eqyt  
C5WCRg5&  
2.NK-kB EU@mrm?  
Gzir>'d2'V  
3.Immunoglobulin superfamily Xou#38&p>  
|be r:1  
4.antigen-presenting cell (APC) |O)deiJRy  
<bx9;1C>zd  
5.death domain .#:,j1L"53  
`HM3YC  
6.CCR and CXCR  hY1|qp  
L@z !,r,  
7.Lectin (or mitogen) ];I|_fXo%  
XsOOkf\_  
8.Clusters of differentiation, CD) ob] lCX)  
|tg?b&QR  
9.B7 family FR}H$R7#  
2 &Byq  
10.Cytotoxic T lymphocyte, CTL) ^c\IZ5  
& .?HuK  
11.IL-15 and IL-15 receptor (IL-15R) @:7gHRJ!  
$CmX &%L=  
12.MHC restriction IPO[J^#Me  
~& 5&s  
13.Affinity-chromatography A&P1M6Of  
{}pqxouE  
14.Cyctosprin A, CsA +?iM$}8!U  
&#@>(u: .  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) eU koVr   
 y"\,%.  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© }%YHm9)  
^Q=y^fx1  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 /Tj"Fl\h  
r.W,-%=bL  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ $G_Q`w=jM  
>J}n@MZ  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ bV`C;RPn  
bw<w u}ED  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© v1r_Z($  
)E:,V~< 8  
ÃâÒßѧרҵ£º cH;TnuX  
YvruK: I  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ g6g$nY@Jm  
3l%,D: ?  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ ?{: D,{+  
o}=.  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ v'@b.R,  
( f,J_  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) iS"8X#[]N  
ISS\uj63M  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) rer|k<k;]G  
*AH^%!kVP  
1. ADCC(antibody dependent cell-mediated cytotoxicity) xHB/]Vd-  
nMG rG  
2. »·æß¾úËØ(cyclosporin) JzMZB"Z?  
#9`rXEz  
3. KIR(killer cell inhibitory receptor) B:-U`CHHQ  
4TUtY:  
4. HLDA(human leucocyte differentiation antigen) e40udLH~x  
$J"%I$%X=  
5. Interleukin 18(IL-18) YOV :  
7qg<[  
6. ÕûºÏËØ(integrin) W|d pFh`  
94|yvh.B  
7. Fas/FasL 8/3u/  
H&X:!xa5  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) aDL)|>"Q  
tAqA^f*{  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) f=ac I|w  
)N(9pnyZH  
10. Th1/Th2 dEA SvD'  
G#H9g PY  
11. »ùÒòÒßÃç(DNAÒßÃç) RF_[?O)Q  
qy_%~c87  
12. chemokines and chemokine receptor i&`!|X-=R  
I%@e @Dm,h  
13. ÃâÒßÄÍÊÜ pW\z\o/2  
ITyzs4"VV  
14. ¹²´Ì¼¤·Ö×Ó }^"0T-ua  
#?9 Q{0e  
15. ËÀÍö½á¹¹Óò(death domain) S%kS#U${|  
U98_M)-%&  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) -!c IesK;<  
9\ v.qo.  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 0[/vQ+O]2  
14  H'!$  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠtd >,TW=A*  
lop uf/U0  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î b,dr+RB  
P@gt di(Q  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ cC%j!8!  
%M9;I  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå x;j{} %  
EJLQ&oH[  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ Cxm6TO`-;  
?Ko|dmX  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) DLi?'K3t  
R& #tSL  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ d+6]u_J  
L/?]^!.  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ R"+wih  
;/'|WLI9  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»